These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7784126)

  • 1. Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study.
    Ballou WR; Blood J; Chongsuphajaissidhi T; Gordon DM; Heppner DG; Kyle DE; Luxemburger C; Nosten F; Sadoff JC; Singhasivanon P
    Parasitology; 1995; 110 Suppl():S25-36. PubMed ID: 7784126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2003; (1):CD000129. PubMed ID: 12535387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy trial of malaria vaccine SPf66 in Gambian infants.
    D'Alessandro U; Leach A; Drakeley CJ; Bennett S; Olaleye BO; Fegan GW; Jawara M; Langerock P; George MO; Targett GA
    Lancet; 1995 Aug; 346(8973):462-7. PubMed ID: 7637479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WITHDRAWN: Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2007 Jul; 2003(4):CD000129. PubMed ID: 17636596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for preventing malaria.
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2000; (2):CD000129. PubMed ID: 10796492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of malaria vaccines: SPf66--what next?
    Tanner M; Alonso PL
    Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in Thailand.
    Migasena S; Heppner DG; Kyle DE; Chongsuphajaisiddhi T; Gordon DM; Suntharasamai P; Permpanich B; Brockman A; Pitiuttutham P; Wongsrichanalai C; Srisuriya P; Phonrat B; Pavanand K; Viravan C; Ballou WR
    Acta Trop; 1997 Sep; 67(3):215-27. PubMed ID: 9241386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group.
    Nosten F; Luxemburger C; Kyle DE; Ballou WR; Wittes J; Wah E; Chongsuphajaisiddhi T; Gordon DM; White NJ; Sadoff JC; Heppner DG
    Lancet; 1996 Sep; 348(9029):701-7. PubMed ID: 8806288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.
    Kashala O; Amador R; Valero MV; Moreno A; Barbosa A; Nickel B; Daubenberger CA; Guzman F; Pluschke G; Patarroyo ME
    Vaccine; 2002 May; 20(17-18):2263-77. PubMed ID: 12009282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia.
    Nosten F; Luxemburger C; Kyle DE; Gordon DM; Ballou WR; Sadoff JC; Brockman A; Permpanich B; Chongsuphajaisiddhi T; Heppner DG
    Am J Trop Med Hyg; 1997 May; 56(5):526-32. PubMed ID: 9180603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania.
    Acosta CJ; Galindo CM; Schellenberg D; Aponte JJ; Kahigwa E; Urassa H; Schellenberg JR; Masanja H; Hayes R; Kitua AY; Lwilla F; Mshinda H; Menendez C; Tanner M; Alonso PL
    Trop Med Int Health; 1999 May; 4(5):368-76. PubMed ID: 10402973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for preventing malaria (SPf66).
    Graves P; Gelband H
    Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD005966. PubMed ID: 16625647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.
    Bojang KA; Obaro SK; D'Alessandro U; Bennett S; Langerock P; Targett GA; Greenwood BM
    Vaccine; 1998 Jan; 16(1):62-7. PubMed ID: 9607010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first field trials of the chemically synthesized malaria vaccine SPf66: safety, immunogenicity and protectivity.
    Amador R; Moreno A; Valero V; Murillo L; Mora AL; Rojas M; Rocha C; Salcedo M; Guzman F; Espejo F
    Vaccine; 1992; 10(3):179-84. PubMed ID: 1557934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum.
    Alonso PL; Smith TA; Armstrong-Schellenberg JR; Kitua AY; Masanja H; Hayes R; Hurt N; Font F; Menendez C; Kilama WL; Tanner M
    J Infect Dis; 1996 Aug; 174(2):367-72. PubMed ID: 8699068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia.
    Valero MV; Amador LR; Galindo C; Figueroa J; Bello MS; Murillo LA; Mora AL; Patarroyo G; Rocha CL; Rojas M
    Lancet; 1993 Mar; 341(8847):705-10. PubMed ID: 8095622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.
    Millet P; Campbell GH; Sulzer AJ; Grady KK; Pohl J; Aikawa M; Collins WE
    Am J Trop Med Hyg; 1993 Mar; 48(3):424-31. PubMed ID: 7682382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66.
    Bojang KA; Obaro SK; Leach A; D'Alessandro U; Bennett S; Metzger W; Ballou WR; Targett GA; Greenwood BM
    Parasite Immunol; 1997 Dec; 19(12):579-81. PubMed ID: 9458470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.
    Heppner DG; Kester KE; Ockenhouse CF; Tornieporth N; Ofori O; Lyon JA; Stewart VA; Dubois P; Lanar DE; Krzych U; Moris P; Angov E; Cummings JF; Leach A; Hall BT; Dutta S; Schwenk R; Hillier C; Barbosa A; Ware LA; Nair L; Darko CA; Withers MR; Ogutu B; Polhemus ME; Fukuda M; Pichyangkul S; Gettyacamin M; Diggs C; Soisson L; Milman J; Dubois MC; Garçon N; Tucker K; Wittes J; Plowe CV; Thera MA; Duombo OK; Pau MG; Goudsmit J; Ballou WR; Cohen J
    Vaccine; 2005 Mar; 23(17-18):2243-50. PubMed ID: 15755604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States.
    Gordon DM; Duffy PE; Heppner DG; Lyon JA; Williams JS; Scheumann D; Farley L; Stacey D; Haynes JD; Sadoff JC; Ballou WR
    Am J Trop Med Hyg; 1996 Jul; 55(1):63-8. PubMed ID: 8702024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.